TY - JOUR
T1 - Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant
AU - Shikanov, Ariella
AU - Shikanov, Sergey
AU - Vaisman, Boris
AU - Golenser, Jacob
AU - Domb, Abraham J.
PY - 2008/6/24
Y1 - 2008/6/24
N2 - Purpose: The aim of this study was to investigate the effectiveness of paclitaxel controlled release from intratumorally injected polymer. Methods: The effectiveness of paclitaxel-polymer formulation injected intratumorally was tested in mouse bladder tumor model. To determine paclitaxel biodistribution in tumor at predetermined time periods the tumor was excised, frozen and sectioned, and the paclitaxel concentrations were determined in the tumor tissue and in plasma by HPLC. Histopathological evaluation of the necrosis and inflammation was performed on tumor sections. Results: In the paclitaxel/polymer group mice were injected intratumorally with 0.2 ml of the 10% (w/w) paclitaxel formulation, the tumor disappeared completely 5 days after injection, and mice survived till the end of the study (50 days post-tumor cells inoculation). In biodistribution studies, the highest paclitaxel concentration in the tumor tissue was 40 μg/mg 1 day after the intratumoral injection and decreased gradually during 10 days to 5 μg/mg that is still high enough to induce cytotoxic effect, and the necrotic effect of paclitaxel on the tumors was confirmed by histopathology. Conclusions: Treatment with local injection of polymer-paclitaxel formulation inhibited the growth of solid tumors. Distribution studies of paclitaxel after intratumoral injection showed high and effective drug concentrations in tumor.
AB - Purpose: The aim of this study was to investigate the effectiveness of paclitaxel controlled release from intratumorally injected polymer. Methods: The effectiveness of paclitaxel-polymer formulation injected intratumorally was tested in mouse bladder tumor model. To determine paclitaxel biodistribution in tumor at predetermined time periods the tumor was excised, frozen and sectioned, and the paclitaxel concentrations were determined in the tumor tissue and in plasma by HPLC. Histopathological evaluation of the necrosis and inflammation was performed on tumor sections. Results: In the paclitaxel/polymer group mice were injected intratumorally with 0.2 ml of the 10% (w/w) paclitaxel formulation, the tumor disappeared completely 5 days after injection, and mice survived till the end of the study (50 days post-tumor cells inoculation). In biodistribution studies, the highest paclitaxel concentration in the tumor tissue was 40 μg/mg 1 day after the intratumoral injection and decreased gradually during 10 days to 5 μg/mg that is still high enough to induce cytotoxic effect, and the necrotic effect of paclitaxel on the tumors was confirmed by histopathology. Conclusions: Treatment with local injection of polymer-paclitaxel formulation inhibited the growth of solid tumors. Distribution studies of paclitaxel after intratumoral injection showed high and effective drug concentrations in tumor.
KW - Anti-tumor efficacy
KW - Controlled release
KW - Injectable biodegradable polymer
KW - Paclitaxel
KW - Poly(ester anhydride)
KW - Tumor distribution
UR - http://www.scopus.com/inward/record.url?scp=44449102033&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2008.02.028
DO - 10.1016/j.ijpharm.2008.02.028
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18406086
AN - SCOPUS:44449102033
SN - 0378-5173
VL - 358
SP - 114
EP - 120
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -
